Single-center Experience of Over a Hundred Implantations of a Transcutaneous Bone Conduction Device

    loading  Checking for direct PDF access through Ovid


Objective:To assess outcomes with a novel passive transcutaneous bone conduction device (t-BCD).Study Design:Prospective data collection and patient review.Setting:Tertiary referral center.Patients:Patients who underwent implantation with the t-BCD between November 2013 and September 2016.Intervention:Implantation of BAHA Attract.Main Outcome Measures:Surgical outcome, patient reported outcomes including the “Glasgow Benefit Inventory” and the “Client Oriented Scale of Improvement” for adults and the “Speech, Spatial and Qualities of Hearing scale” (SSQ-12) for children.Results:One hundred five patients were implanted. Numbness superior to the incision was commonly noticed. Four patients (3.8%) developed skin tenderness and redness that settled with conservative measures. Among those patients who had a conversion from a percutaneous Bone Conduction Hearing Device (BCHD) to the t-BCD (n=15), 1 (0.9%) developed seroma and 2 (1.9%) developed skin dehiscence at the edge of the implant magnet. Significant improvement in Client Oriented Scale of Improvement and Glasgow Benefit Inventory scores with a global satisfaction of 84% and 77.4% was observed for those previously aided and unaided respectively, with use of the device. A 22% improvement in SSQ-12 mean score was observed in the pediatric population.Conclusion:This is the largest single-center series reported on this t-BCD. The complication rate is small but caution is required in patients of conversion from a percutaneous BCHD. The patients’ satisfaction is high and the need for aftercare is minimal. Cost-effectiveness evaluation of these devices, development of core outcome sets and well-designed, prospective trials to compare the different BCHDs should be the focus of future research.

    loading  Loading Related Articles